Company intelligence / Profile preview
Mologen AG
Berlin, Berlin, Germanymologen.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Other
01
Overview
Mologen had a Phase III study for Lefitolimod in metastatic colorectal cancer, Phase II trial for small-cell lung cancer, and Phase Ib/IIa study for HIV treatment. They also had a Phase I combination study with checkpoint inhibitor Yervoy for advanced solid tumors.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- DNA immunomodulatorCell-based therapiesDNA vaccinesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Aarhus University Hospital in DenmarkMD Anderson Cancer Center at the University of Texas
Beyond the preview
Go deeper on Mologen AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mologen AG.